AnaptysBio (NASDAQ:ANAB) Stock Rating Upgraded by Wall Street Zen

AnaptysBio (NASDAQ:ANAB) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other analysts have also issued research reports about the stock. Leerink Partners reduced their price target on shares of AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of AnaptysBio in a research note on Tuesday, September 22nd. HC Wainwright restated a “buy” rating and issued a $95.00 target price on shares of AnaptysBio in a research report on Tuesday, September 22nd. Scotiabank downgraded AnaptysBio to a “hold” rating and set a $70.00 target price on the stock. in a research report on Tuesday, August 25th. Finally, TD Cowen lowered their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and an average price target of $79.15.

AnaptysBio Stock Performance

AnaptysBio stock opened at $51.00 on Friday. The company has a 50-day moving average price of $55.38 and a 200 day moving average price of $59.08. AnaptysBio has a 12-month low of $13.86 and a 12-month high of $72.36. The stock has a market cap of $1.52 billion, a P/E ratio of 9.50 and a beta of 0.71.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $5.57. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. The company had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million. During the same period in the previous year, the business posted ($1.30) EPS. As a group, analysts forecast that AnaptysBio will post -1.48 EPS for the current year.

Hedge Funds Weigh In On AnaptysBio

Hedge funds have recently made changes to their positions in the stock. Tema ETFs LLC grew its position in shares of AnaptysBio by 0.6% during the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after buying an additional 201 shares in the last quarter. Arizona State Retirement System increased its stake in shares of AnaptysBio by 13.5% during the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after buying an additional 518 shares during the period. Persistent Asset Partners Ltd acquired a new stake in AnaptysBio in the second quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd raised its holdings in AnaptysBio by 940.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 1,383 shares in the last quarter. Finally, Group One Trading LLC purchased a new position in AnaptysBio in the second quarter worth approximately $140,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.